Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 2.9% - What's Next?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s share price traded down 2.9% during mid-day trading on Tuesday . The stock traded as low as $7.60 and last traded at $7.27. 58,376 shares changed hands during mid-day trading, a decline of 96% from the average session volume of 1,425,839 shares. The stock had previously closed at $7.49.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of analyst reports. BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target on the stock. Chardan Capital reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. Scotiabank started coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price for the company. Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. Finally, Piper Sandler decreased their price target on Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $47.46.

Dyne Therapeutics Trading Up 0.9 %

The company's 50 day moving average price is $11.86 and its two-hundred day moving average price is $21.34. The stock has a market cap of $796.37 million, a P/E ratio of -1.98 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Insider Activity

In other news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 in the last ninety days. Corporate insiders own 20.77% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its position in shares of Dyne Therapeutics by 0.3% in the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after acquiring an additional 698 shares in the last quarter. Summit Investment Advisors Inc. grew its position in shares of Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock worth $203,000 after purchasing an additional 721 shares in the last quarter. KBC Group NV raised its stake in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares during the period. E Fund Management Co. Ltd. lifted its holdings in Dyne Therapeutics by 11.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock worth $279,000 after purchasing an additional 1,249 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics in the 4th quarter worth approximately $50,000. Institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.